We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Decision that design-defect claims against generic manufacturers are pre-empted may have broad impact

26 June 2013

Supreme Court Alert

On 24 June 2013, in Mutual Pharmaceutical Co. v. Bartlett, No. 12-142, 570 U.S. __ (2013), the United States Supreme Court held that generic manufacturers cannot be liable for state tort design-defect claims because federal law prevents them from changing a drug’s design.

Read more: Decision that design-defect claims against generic manufacturers are pre-empted may have broad impact

The team

Loading data